<DOC>
	<DOCNO>NCT00148291</DOCNO>
	<brief_summary>Vinorelbine currently standard treatment elderly patient advance non-small cell lung cancer ( NSCLC ) . Docetaxel also show promising result elderly patient phase II study . We conduct randomized phase III trial evaluate whether docetaxel provide well overall survival vinorelbine elderly patient advance NSCLC .</brief_summary>
	<brief_title>Phase III Study Docetaxel Vs Vinorelbine Elderly Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Chemotherapy radiotherapynaïve patient histologically cytologically diagnosis stage IIIB IV NSCLC ≧ 70 year old measurable assessable disease eligible trial . They life expectancy least 3 month . Additional entry criterion follow : ( ) performance status ( PS ) 0 2 Eastern Cooperative Oncology Group scale ; ( b ) adequate function bone marrow ( leukocyte count ≧ 4,000/μL , absolute neutrophil count ≧ 2,000/μL , hemoglobin concentration ≧ 9.5 g/dL , platelet count ≧ 100,000/μL ) , kidney ( serum creatinine ≦ 1.2 mg/dL ) , liver ( total bilirubin ≦ 1.5 time institutional upper limit normal , transaminase AST ALT ≦ 2.5 time institutional upper limit normal ) . Patients symptomatic brain metastasis apparent dementia ineligible . Patients active concomitant malignancy , massive pleural effusion ascites , active infection , severe heart disease , grade 2 high ECG abnormality , uncontrolled diabetes mellitus , ileus , pulmonary fibrosis , diarrhea , bleed tendency exclude .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>